Ruxolitinib for treating polycythaemia vera (terminated appraisal) (TA356)
NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating polycythaemia vera...
Search results
1414 results
-
-
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)
Evidence-based recommendations on vedolizumab (Entyvio) for moderately to severely active Crohn's disease if TNF-alpha therapy has not worked or...
-
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)
Evidence-based recommendations on edoxaban (Lixiana) for treating and preventing deep vein thrombosis (DVT) and pulmonary embolism
-
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) (TA353)
NICE is unable to make recommendations about the use of bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or…
-
Guidance on the use of patient-education models for diabetes (TA60)
This guidance has been replaced by NICE guideline NG17.
-
Guidance on the use of long‑acting insulin analogues for the treatment of diabetes – insulin glargine (TA53)
This guidance has been replaced by NICE guideline NG17.
-
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA349)
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating diabetic macular oedema
-
Secukinumab for treating moderate to severe plaque psoriasis (TA350)
Evidence-based recommendations on secukinumab (Cosentyx) for treating moderate to severe plaque psoriasis
-
Aflibercept for treating diabetic macular oedema (TA346)
Evidence-based recommendations on aflibercept (Eylea) for treating diabetic macular oedema
-
Everolimus for preventing organ rejection in liver transplantation (TA348)
Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in people having a liver transplant
-
Naloxegol for treating opioid‑induced constipation (TA345)
Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation that has had inadequate response to laxatives
-
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (TA347)
Evidence-based recommendations on nintedanib (Vargatef) for treating locally advanced, metastatic, or locally recurrent non-small-cell lung cancer
-
Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) (TA351)
NICE is unable to make recommendations about the use of cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary…
-
Omalizumab for previously treated chronic spontaneous urticaria (TA339)
Evidence-based recommendations on omalizumab (Xolair) for treating previously treated severe chronic spontaneous urticaria (hives)
-
Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)
Evidence-based recommendations on vedolizumab (Entyvio) for treating moderately to severely active ulcerative colitis in adults
-
Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)
Evidence-based recommendations on apixaban (Eliquis) for treating and preventing deep vein thrombosis (DVT) or pulmonary embolism
-
Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index (DG17)
This guideline has been updated and replaced by NICE guideline NG131.
-
Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (TA344)
This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.
-
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for treating untreated chronic lymphocytic leukaemia
-
Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib (TA338)
This guidance has been updated and replaced by NICE technology appraisal guidance 427.
-
Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)
Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of overt hepatic encephalopathy
-
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing adverse outcomes after acute management of acute coronary syndrome (ACS)
-
Empagliflozin in combination therapy for treating type 2 diabetes (TA336)
Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes
-
Safe midwifery staffing for maternity settings (NG4)
This guideline covers safe midwifery staffing in all maternity settings, including at home, in the community, in day assessment units, in obstetric units, and in units led by midwives (both alongside hospitals and free-standing). It aims to improve maternity care by giving advice on monitoring staffing levels and actions to take if there are not enough midwives to meet the needs of women and babies in the service.
-
Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C (TA331)
The guidance has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.
-
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)
Evidence-based recommendations on infliximab (Remicade, Inflectra, Remsima) adalimumab (Humira) and golimumab (Simponi) for ulcerative colitis after..
-
Sofosbuvir for treating chronic hepatitis C (TA330)
Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)
-
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)
Evidence-based recommendations on axitinib (Inlyta) for treating advanced renal cell carcinoma (RCC) (kidney cancer) when prior systemic treatment has failed
-
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (TA334)
NICE is unable to make recommendations about regorafenib for metastatic colorectal cancer because no evidence submission was received from Bayer for the..
-
Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer (TA332)
This appraisal has been withdrawn. This is because the marketing authorisation for sipuleucel-T was withdrawn on 19 May 2015.
-
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)
Evidence-based recommendations on vemurafenib (Zelboraf) for treating advanced BRAF V600-positive malignant melanoma in adults
-
Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) (TA328)
This guidance has been updated and replaced by NICE technology appraisal guidance 604.
-
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327)
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treatment and secondary prevention of deep vein thrombosis (DVT) or pulmonary embolism
-
Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)
Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the
-
Liraglutide for the treatment of type 2 diabetes mellitus (TA203)
This guidance has been updated and replaced by NICE guideline NG28.
-
Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)
Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in people with alcohol dependence
-
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA326)
Evidence-based recommendations on imatinib (Glivec) for adjuvant treatment of gastrointestinal stromal tumours (cancers in the digestive track)
-
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (TA324)
Evidence-based recommendations on dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block
-
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323)
Evidence-recommendations on erythropoiesis-stimulation agents (epoetin alfa, beta, theta and zeta and darbepoetin alfa) for anaemia in people with cancer..
-
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block (TA88)
Evidence-based recommendations on dual-chamber pacemakers for symptomatic bradycardia (slow heart rate) due to sick sinus syndrome and/or atrioventricular block
-
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)
Evidence-based recommendations on dabrafenib (Tafinlar) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation
-
Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, ARCHITECT STAT High Sensitive Troponin-I and AccuTnI+3 assays) (DG15)
This guidance has been updated and replaced by NICE diagnostics guidance 40.
-
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)
Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis (MS/RRMS)
-
Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (DG13)
NICE has assessed 3 viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems), to help the NHS decide whether to use these products
-
Lubiprostone for treating chronic idiopathic constipation (TA318)
This guidance has been withdrawn because Takeda has discontinued lubiprostone (Amitiza).
-
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (TA317)
Evidence-based recommendations on prasugrel (Efient) with percutaneous coronary intervention (PCI) for treating acute coronary syndrome (ACS)
-
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)
Evidence-based recommendations on ipilimumab (Yervoy) for previously untreated advanced (unresectable or metastatic) melanoma in adults
-
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)
Evidence-based recommendations on enzalutamide (Xtandi) for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen
-
Safe staffing for nursing in adult inpatient wards in acute hospitals (SG1)
This guideline covers organisational and managerial approaches to safe nurse staffing of inpatient wards for people aged 18 and over in acute hospitals. It aims to ensure that patients receive the nursing care they need, regardless of the ward to which they are allocated, the time of the day, or the day of the week.
-
Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (TA314)
Evidence-based recommendations on implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) for arrhythmias and heart failure